Roche reaffirms 2026 outlook for mid-single-digit sales growth at constant exchange rates
- Roche reaffirmed its 2026 outlook for mid-single-digit sales growth at constant exchange rates.
- Core earnings per share are targeted to grow in the high single digits at constant exchange rates.
- The group aims to raise its dividend in Swiss francs again.
- Nine-month sales reached CHF 46.49 billion, up 6% at constant exchange rates, driven by strong demand for medicines and diagnostics.
- Third-quarter sales rose 7% at constant exchange rates, with growth in Swiss francs reaching 8% as currency effects reversed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220100OMX_____CNEWS_DE_GNW1001279125_de) on October 22, 2026, and is solely responsible for the information contained therein.